Microsoft® plans to release Windows 11 this week. Though you may be tempted to upgrade to access new features and functionality, please don’t! The operating system has not been certified for QS/1 applications yet. Once it has been certified, communication will follow to inform customers that it’s safe to upgrade or purchase new hardware with Windows 11 preloaded.
Ninth Amendment to the PREP Act
The Department of Health and Human Services (HHS) amended the Public Readiness and Emergency Preparedness (PREP) Act declaration, providing a pathway for increased access to COVID-19 therapeutics, particularly in surge states with rising numbers of COVID-19 cases and in rural areas where access to inpatient and outpatient services may be more limited.
The Ninth Amendment to the COVID-19 PREP Act Declaration provides liability immunity to and expands the scope of authority for licensed pharmacists to order and administer select COVID-19 therapeutics to populations authorized by the Food and Drug Administration (FDA) and for pharmacy technicians and pharmacy interns to administer, under pharmacist supervision, COVID-19 therapeutics to populations authorized by the FDA when specific criteria are met.
Pharmacists have more than proven their invaluable role on the patient healthcare team. With persistent advocacy, they’re making strides towards provider status and improving overall health outcomes. A few states have passed bills allowing pharmacists to treat HIV-exposed and HIV-positive patients.
In 2019, California became the first state to authorize pharmacists to treat HIV patients using post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PreP). This summer, four more states followed suit:
Nevada
Missouri
Oregon
North Carolina (PEP only)
What is your state doing to expand the scope of pharmacy and address the needs in your community? Make sure you’re involved in local associations and at the national level – making your voice heard.
Are you going to the NCPA Annual Convention October 9-12? If so, visit the RedSail team at booth #907. RedSail is the exclusive sponsor of the Expo Reception on October 10 from 3-4 PM (ET), and we’d love to connect with you in person.
RedSail’s all-new, cloud-based IVR provides the freedom of a truly modern phone system. With 99.999% uptime, a self-service interface, analytics dashboards, and more, you can enhance your customers’ experience and provide them with the convenience they want and deserve.
Display Your OTC Products with Pointy's Free Integration
Attract customers to your pharmacy and expand your digital presence with Pointy from Google. It’s easy! Display your products online – using simple, free integration with your POS system. Want to know one of the best parts? No data entry is needed.
Key Features:
A Pointy Page to showcase live inventory
Ability to add to your Business Profile on Google, so shoppers can see items in stock
High-intent ads that display at the top of search results
A Retailer Dashboard for invaluable insights from ads
For more information, read our QPath Blog post here.
To remain compliant and continue using MethCheck integration with POS, customers must update to Pharmacy Systems Service Pack 19.1.35g or higher. This update must be completed by November 1, 2021.
The Community Pharmacy Enhanced Services Network (CPESN) is reimagining healthcare delivery with patients at the center of care. This clinically integrated network of high-performing pharmacies is growing. Want to know more about the movement? Attend an introductory webinar hosted by a community pharmacy owner.
Beginning November 15, 2021, healthcare professionals prescribing clozapine, pharmacists and authorized representatives of pharmacies dispensing clozapine, and wholesalers/distributors distributing clozapine must recertify or reenroll in the Clozapine Risk Evaluation and Mitigation Strategy (REMS) Program. All stakeholders may start to recertify and reenroll now.
The REMS administrator has changed, and the current “switch” pharmacy management system is being removed as a method to verify clozapine dispensing. Pharmacists will no longer use the switch system to obtain a pre-dispense authorization, now called a REMS dispense authorization (RDA). To obtain an RDA, visit the Clozapine REMS website or call the Clozapine REMS Contact Center at 888.586.0758.
